Genvec, Inc. – Nasdaq: GNVC
Genvec, Inc shares rose over 75% in today’s trading. The shares, traded on the Nasdaq under ticker GNVC, ended yesterday at $4.97. Today they rose to a high of $10.44 before ending the session at $8.79. Volumes for GNVC averaged around 100,000 but today volume reached over 17 million.
GenVec is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging its AdenoVerse™ gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenovectored product candidates that can deliver on the promise of gene-based medicine. On January 5th, Genvec, Inc. an exclusive option agreement with Washington University in St. Louis, MO to license intellectual property and technology related to gene editing and pulmonary endothelial cell targeting.
A single firm follows Genvec and their analyst gives GNVC a rating of “Strong Buy”. Genvec has never experienced positive EPS and last year reported a loss of $3.90 EPS. While Genvec has reported sales each year since 2011, 2015 represented its weakest year – Genvec posted sales of only $900,000 versus $17.7 million in 2011.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
|Last Price a/o 4:00 PM EST||$ 8.79|
|Market Cap||$22.33 million|
|Shares Outstanding||2.54 million|
|Share Float||1.72 million|
|Short Interest Ratio||0.39|